Due to MYC-mediated metabolic reprogramming, tumour cells become dependent on the de novo biosynthesis pathway to sustain cell proliferation, suggesting that these cells are highly sensitive to inhibitors that target this metabolic pathway [12]. This evidence concerns the gene MYC and neoplasm.